Trial Profile
A Multinational, Multicenter, Randomized, Comparative, Open-label, Phase 3 Study to Assess the Immunogenicity and Safety of DTaP-IPV (Diphtheria-tetanus-acellular Pertussis-inactivated Poliovirus) Vaccine Administered to Healthy Infants
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs BR-8002 (Primary) ; DTaP vaccine; Poliovirus vaccine inactivated
- Indications Diphtheria; Pertussis; Poliomyelitis; Tetanus
- Focus Pharmacodynamics
- Acronyms VENUS
- Sponsors Boryung Pharmaceutical
- 25 Jun 2023 Status changed from active, no longer recruiting to completed.
- 16 Jan 2018 Planned End Date changed from 1 Apr 2018 to 1 Jun 2018.
- 16 Jan 2018 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.